Search

Displaying results 8601 - 8610 of 10000 in total
  1. Drug

    Gamma cyclodextrin

    go.drugbank.com/drugs/DB19173
    Investigational

    Gamma cyclodextrin is under investigation in clinical trial NCT03931057 (The use of ADV6209 for Premedication in Pediatric Anesthesia).

  2. Drug

    Flufenoxuron

    go.drugbank.com/drugs/DB15006
    Experimental

    Flufenoxuron is under investigation in clinical trial NCT00922870 (Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock).

  3. Drug

    BPI-3016

    go.drugbank.com/drugs/DB15158
    Investigational

    BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects).

  4. Drug

    Telaglenastat

    go.drugbank.com/drugs/DB15232
    Investigational

    Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).

  5. Drug

    Dihematoporphyrin ether

    go.drugbank.com/drugs/DB15351
    Investigational

    Dihematoporphyrin ether is under investigation in clinical trial NCT00118222 (High Light and Low Light Dose PDT in Glioma).

  6. Drug

    Histamine glutarimide

    go.drugbank.com/drugs/DB16016
    Investigational

    Histamine glutarimide is under investigation in clinical trial NCT03450434 (XC8 in the Treatment of Patients With Bronchial Asthma).

  7. Drug

    VLX-1570

    go.drugbank.com/drugs/DB16030
    Investigational

    VLX-1570 is under investigation in clinical trial NCT02372240 (A Study of VLX1570 and Dexamethasone in Myeloma Patients).

  8. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

  9. Drug

    Methapyrilene

    go.drugbank.com/drugs/DB04819
    ApprovedWithdrawn

    Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

  10. Drug

    Tarazepide

    go.drugbank.com/drugs/DB06435
    Experimental